nodes	percent_of_prediction	percent_of_DWPC	metapath
Metoclopramide—Sunitinib—ALK—lymphatic system cancer	0.0624	1	CrCbGaD
Metoclopramide—Consciousness abnormal—Vincristine—lymphatic system cancer	0.0566	0.0603	CcSEcCtD
Metoclopramide—Amenorrhoea—Mechlorethamine—lymphatic system cancer	0.0282	0.0301	CcSEcCtD
Metoclopramide—Supraventricular tachycardia—Fludarabine—lymphatic system cancer	0.0245	0.0261	CcSEcCtD
Metoclopramide—Altered state of consciousness—Vincristine—lymphatic system cancer	0.0213	0.0227	CcSEcCtD
Metoclopramide—Respiratory failure—Fludarabine—lymphatic system cancer	0.0164	0.0174	CcSEcCtD
Metoclopramide—Depression—Mechlorethamine—lymphatic system cancer	0.0138	0.0147	CcSEcCtD
Metoclopramide—Jaundice—Mechlorethamine—lymphatic system cancer	0.0135	0.0144	CcSEcCtD
Metoclopramide—Hepatotoxicity—Carmustine—lymphatic system cancer	0.0133	0.0142	CcSEcCtD
Metoclopramide—Agranulocytosis—Mechlorethamine—lymphatic system cancer	0.0129	0.0138	CcSEcCtD
Metoclopramide—Cardiac failure congestive—Fludarabine—lymphatic system cancer	0.0129	0.0137	CcSEcCtD
Metoclopramide—Visual disturbance—Fludarabine—lymphatic system cancer	0.0123	0.0131	CcSEcCtD
Metoclopramide—Wheezing—Bleomycin—lymphatic system cancer	0.0114	0.0122	CcSEcCtD
Metoclopramide—Bronchospasm—Teniposide—lymphatic system cancer	0.0113	0.012	CcSEcCtD
Metoclopramide—Amenorrhoea—Mitoxantrone—lymphatic system cancer	0.0109	0.0116	CcSEcCtD
Metoclopramide—Neutropenia—Teniposide—lymphatic system cancer	0.0107	0.0114	CcSEcCtD
Metoclopramide—Respiratory failure—Vincristine—lymphatic system cancer	0.00999	0.0107	CcSEcCtD
Metoclopramide—Urinary incontinence—Carmustine—lymphatic system cancer	0.00993	0.0106	CcSEcCtD
Metoclopramide—Leukopenia—Mechlorethamine—lymphatic system cancer	0.0097	0.0103	CcSEcCtD
Metoclopramide—Neutropenia—Fludarabine—lymphatic system cancer	0.00942	0.0101	CcSEcCtD
Metoclopramide—Gynaecomastia—Carmustine—lymphatic system cancer	0.0092	0.00981	CcSEcCtD
Metoclopramide—Flushing—Teniposide—lymphatic system cancer	0.00852	0.00909	CcSEcCtD
Metoclopramide—Visual impairment—Fludarabine—lymphatic system cancer	0.00777	0.00829	CcSEcCtD
Metoclopramide—Cardiac failure congestive—Mitoxantrone—lymphatic system cancer	0.00765	0.00816	CcSEcCtD
Metoclopramide—Agitation—Teniposide—lymphatic system cancer	0.00734	0.00783	CcSEcCtD
Metoclopramide—Bronchospasm—Bleomycin—lymphatic system cancer	0.00727	0.00775	CcSEcCtD
Metoclopramide—Leukopenia—Teniposide—lymphatic system cancer	0.00715	0.00763	CcSEcCtD
Metoclopramide—Hypertension—Teniposide—lymphatic system cancer	0.0069	0.00736	CcSEcCtD
Metoclopramide—Cardiac arrest—Vincristine—lymphatic system cancer	0.00677	0.00722	CcSEcCtD
Metoclopramide—Confusional state—Teniposide—lymphatic system cancer	0.00658	0.00701	CcSEcCtD
Metoclopramide—Oedema—Teniposide—lymphatic system cancer	0.00652	0.00696	CcSEcCtD
Metoclopramide—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00652	0.00695	CcSEcCtD
Metoclopramide—Agitation—Fludarabine—lymphatic system cancer	0.00645	0.00688	CcSEcCtD
Metoclopramide—Tachycardia—Teniposide—lymphatic system cancer	0.00636	0.00679	CcSEcCtD
Metoclopramide—Leukopenia—Fludarabine—lymphatic system cancer	0.00629	0.0067	CcSEcCtD
Metoclopramide—Hepatotoxicity—Methotrexate—lymphatic system cancer	0.00617	0.00658	CcSEcCtD
Metoclopramide—Hypotension—Teniposide—lymphatic system cancer	0.00609	0.0065	CcSEcCtD
Metoclopramide—Convulsion—Fludarabine—lymphatic system cancer	0.00608	0.00649	CcSEcCtD
Metoclopramide—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00605	0.00645	CcSEcCtD
Metoclopramide—Neutropenia—Carmustine—lymphatic system cancer	0.00603	0.00643	CcSEcCtD
Metoclopramide—Dyspnoea—Teniposide—lymphatic system cancer	0.00581	0.0062	CcSEcCtD
Metoclopramide—Confusional state—Fludarabine—lymphatic system cancer	0.00578	0.00616	CcSEcCtD
Metoclopramide—Neutropenia—Vincristine—lymphatic system cancer	0.00576	0.00614	CcSEcCtD
Metoclopramide—Depression—Carmustine—lymphatic system cancer	0.00573	0.00612	CcSEcCtD
Metoclopramide—Oedema—Fludarabine—lymphatic system cancer	0.00573	0.00611	CcSEcCtD
Metoclopramide—Erectile dysfunction—Vincristine—lymphatic system cancer	0.00567	0.00605	CcSEcCtD
Metoclopramide—Neutropenia—Mitoxantrone—lymphatic system cancer	0.00561	0.00598	CcSEcCtD
Metoclopramide—Rash—Mechlorethamine—lymphatic system cancer	0.00558	0.00595	CcSEcCtD
Metoclopramide—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00557	0.00594	CcSEcCtD
Metoclopramide—Erectile dysfunction—Mitoxantrone—lymphatic system cancer	0.00552	0.00589	CcSEcCtD
Metoclopramide—Flushing—Bleomycin—lymphatic system cancer	0.00549	0.00585	CcSEcCtD
Metoclopramide—Depression—Vincristine—lymphatic system cancer	0.00547	0.00584	CcSEcCtD
Metoclopramide—Feeling abnormal—Teniposide—lymphatic system cancer	0.00537	0.00573	CcSEcCtD
Metoclopramide—Drowsiness—Mitoxantrone—lymphatic system cancer	0.00535	0.0057	CcSEcCtD
Metoclopramide—Nausea—Mechlorethamine—lymphatic system cancer	0.00525	0.0056	CcSEcCtD
Metoclopramide—Jaundice—Mitoxantrone—lymphatic system cancer	0.00521	0.00556	CcSEcCtD
Metoclopramide—Urticaria—Teniposide—lymphatic system cancer	0.00518	0.00553	CcSEcCtD
Metoclopramide—Body temperature increased—Teniposide—lymphatic system cancer	0.00515	0.0055	CcSEcCtD
Metoclopramide—Hallucination—Carmustine—lymphatic system cancer	0.00514	0.00548	CcSEcCtD
Metoclopramide—Dyspnoea—Fludarabine—lymphatic system cancer	0.00511	0.00545	CcSEcCtD
Metoclopramide—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.00499	0.00532	CcSEcCtD
Metoclopramide—Visual impairment—Carmustine—lymphatic system cancer	0.00498	0.00531	CcSEcCtD
Metoclopramide—Fatigue—Fludarabine—lymphatic system cancer	0.00494	0.00527	CcSEcCtD
Metoclopramide—Hallucination—Vincristine—lymphatic system cancer	0.0049	0.00523	CcSEcCtD
Metoclopramide—Bradycardia—Mitoxantrone—lymphatic system cancer	0.00489	0.00521	CcSEcCtD
Metoclopramide—Respiratory failure—Methotrexate—lymphatic system cancer	0.00485	0.00517	CcSEcCtD
Metoclopramide—Hypersensitivity—Teniposide—lymphatic system cancer	0.0048	0.00512	CcSEcCtD
Metoclopramide—Flushing—Carmustine—lymphatic system cancer	0.00479	0.00511	CcSEcCtD
Metoclopramide—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00472	0.00504	CcSEcCtD
Metoclopramide—Asthenia—Teniposide—lymphatic system cancer	0.00468	0.00499	CcSEcCtD
Metoclopramide—Leukopenia—Bleomycin—lymphatic system cancer	0.00461	0.00492	CcSEcCtD
Metoclopramide—Body temperature increased—Fludarabine—lymphatic system cancer	0.00453	0.00483	CcSEcCtD
Metoclopramide—Diarrhoea—Teniposide—lymphatic system cancer	0.00446	0.00476	CcSEcCtD
Metoclopramide—Gynaecomastia—Methotrexate—lymphatic system cancer	0.00426	0.00454	CcSEcCtD
Metoclopramide—Confusional state—Bleomycin—lymphatic system cancer	0.00424	0.00452	CcSEcCtD
Metoclopramide—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00422	0.0045	CcSEcCtD
Metoclopramide—Tremor—Carmustine—lymphatic system cancer	0.00421	0.00449	CcSEcCtD
Metoclopramide—Oedema—Bleomycin—lymphatic system cancer	0.0042	0.00448	CcSEcCtD
Metoclopramide—Agitation—Carmustine—lymphatic system cancer	0.00413	0.00441	CcSEcCtD
Metoclopramide—Asthenia—Fludarabine—lymphatic system cancer	0.00411	0.00439	CcSEcCtD
Metoclopramide—Rash—Teniposide—lymphatic system cancer	0.00411	0.00439	CcSEcCtD
Metoclopramide—Dermatitis—Teniposide—lymphatic system cancer	0.00411	0.00438	CcSEcCtD
Metoclopramide—Headache—Teniposide—lymphatic system cancer	0.00409	0.00436	CcSEcCtD
Metoclopramide—Leukopenia—Carmustine—lymphatic system cancer	0.00402	0.00429	CcSEcCtD
Metoclopramide—Agitation—Vincristine—lymphatic system cancer	0.00394	0.00421	CcSEcCtD
Metoclopramide—Hypotension—Bleomycin—lymphatic system cancer	0.00393	0.00419	CcSEcCtD
Metoclopramide—Diarrhoea—Fludarabine—lymphatic system cancer	0.00392	0.00418	CcSEcCtD
Metoclopramide—Convulsion—Carmustine—lymphatic system cancer	0.00389	0.00415	CcSEcCtD
Metoclopramide—Hypertension—Carmustine—lymphatic system cancer	0.00388	0.00414	CcSEcCtD
Metoclopramide—Nausea—Teniposide—lymphatic system cancer	0.00387	0.00413	CcSEcCtD
Metoclopramide—Leukopenia—Vincristine—lymphatic system cancer	0.00384	0.0041	CcSEcCtD
Metoclopramide—Anxiety—Carmustine—lymphatic system cancer	0.00381	0.00407	CcSEcCtD
Metoclopramide—Dyspnoea—Bleomycin—lymphatic system cancer	0.00375	0.004	CcSEcCtD
Metoclopramide—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00374	0.00399	CcSEcCtD
Metoclopramide—Convulsion—Vincristine—lymphatic system cancer	0.00372	0.00396	CcSEcCtD
Metoclopramide—Hypertension—Vincristine—lymphatic system cancer	0.0037	0.00395	CcSEcCtD
Metoclopramide—Confusional state—Carmustine—lymphatic system cancer	0.0037	0.00394	CcSEcCtD
Metoclopramide—Oedema—Carmustine—lymphatic system cancer	0.00367	0.00391	CcSEcCtD
Metoclopramide—Visual disturbance—Methotrexate—lymphatic system cancer	0.00365	0.00389	CcSEcCtD
Metoclopramide—Convulsion—Mitoxantrone—lymphatic system cancer	0.00362	0.00386	CcSEcCtD
Metoclopramide—Rash—Fludarabine—lymphatic system cancer	0.00361	0.00385	CcSEcCtD
Metoclopramide—Dermatitis—Fludarabine—lymphatic system cancer	0.00361	0.00385	CcSEcCtD
Metoclopramide—Hypertension—Mitoxantrone—lymphatic system cancer	0.00361	0.00385	CcSEcCtD
Metoclopramide—Headache—Fludarabine—lymphatic system cancer	0.00359	0.00383	CcSEcCtD
Metoclopramide—Tachycardia—Carmustine—lymphatic system cancer	0.00358	0.00382	CcSEcCtD
Metoclopramide—Anxiety—Mitoxantrone—lymphatic system cancer	0.00354	0.00378	CcSEcCtD
Metoclopramide—Oedema—Vincristine—lymphatic system cancer	0.0035	0.00373	CcSEcCtD
Metoclopramide—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00346	0.00369	CcSEcCtD
Metoclopramide—Confusional state—Mitoxantrone—lymphatic system cancer	0.00344	0.00367	CcSEcCtD
Metoclopramide—Hypotension—Carmustine—lymphatic system cancer	0.00343	0.00366	CcSEcCtD
Metoclopramide—Oedema—Mitoxantrone—lymphatic system cancer	0.00341	0.00364	CcSEcCtD
Metoclopramide—Nausea—Fludarabine—lymphatic system cancer	0.0034	0.00363	CcSEcCtD
Metoclopramide—Urticaria—Bleomycin—lymphatic system cancer	0.00334	0.00356	CcSEcCtD
Metoclopramide—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00333	0.00355	CcSEcCtD
Metoclopramide—Body temperature increased—Bleomycin—lymphatic system cancer	0.00332	0.00354	CcSEcCtD
Metoclopramide—Insomnia—Carmustine—lymphatic system cancer	0.00332	0.00354	CcSEcCtD
Metoclopramide—Hypotension—Vincristine—lymphatic system cancer	0.00327	0.00349	CcSEcCtD
Metoclopramide—Dyspnoea—Carmustine—lymphatic system cancer	0.00327	0.00349	CcSEcCtD
Metoclopramide—Somnolence—Carmustine—lymphatic system cancer	0.00326	0.00348	CcSEcCtD
Metoclopramide—Hypotension—Mitoxantrone—lymphatic system cancer	0.00319	0.0034	CcSEcCtD
Metoclopramide—Insomnia—Vincristine—lymphatic system cancer	0.00317	0.00338	CcSEcCtD
Metoclopramide—Hypersensitivity—Bleomycin—lymphatic system cancer	0.0031	0.0033	CcSEcCtD
Metoclopramide—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00304	0.00324	CcSEcCtD
Metoclopramide—Somnolence—Mitoxantrone—lymphatic system cancer	0.00303	0.00323	CcSEcCtD
Metoclopramide—Feeling abnormal—Carmustine—lymphatic system cancer	0.00302	0.00322	CcSEcCtD
Metoclopramide—Fatigue—Vincristine—lymphatic system cancer	0.00302	0.00322	CcSEcCtD
Metoclopramide—Asthenia—Bleomycin—lymphatic system cancer	0.00301	0.00322	CcSEcCtD
Metoclopramide—Asthma—Methotrexate—lymphatic system cancer	0.00299	0.00319	CcSEcCtD
Metoclopramide—Fatigue—Mitoxantrone—lymphatic system cancer	0.00294	0.00314	CcSEcCtD
Metoclopramide—Body temperature increased—Carmustine—lymphatic system cancer	0.0029	0.00309	CcSEcCtD
Metoclopramide—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00281	0.003	CcSEcCtD
Metoclopramide—Neutropenia—Methotrexate—lymphatic system cancer	0.00279	0.00298	CcSEcCtD
Metoclopramide—Body temperature increased—Vincristine—lymphatic system cancer	0.00277	0.00295	CcSEcCtD
Metoclopramide—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.00275	0.00293	CcSEcCtD
Metoclopramide—Urticaria—Mitoxantrone—lymphatic system cancer	0.00271	0.00289	CcSEcCtD
Metoclopramide—Hypersensitivity—Carmustine—lymphatic system cancer	0.0027	0.00288	CcSEcCtD
Metoclopramide—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.0027	0.00288	CcSEcCtD
Metoclopramide—Drowsiness—Methotrexate—lymphatic system cancer	0.00266	0.00284	CcSEcCtD
Metoclopramide—Depression—Methotrexate—lymphatic system cancer	0.00266	0.00283	CcSEcCtD
Metoclopramide—Rash—Bleomycin—lymphatic system cancer	0.00265	0.00283	CcSEcCtD
Metoclopramide—Dermatitis—Bleomycin—lymphatic system cancer	0.00265	0.00282	CcSEcCtD
Metoclopramide—Asthenia—Carmustine—lymphatic system cancer	0.00263	0.00281	CcSEcCtD
Metoclopramide—Hypersensitivity—Vincristine—lymphatic system cancer	0.00258	0.00275	CcSEcCtD
Metoclopramide—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00251	0.00268	CcSEcCtD
Metoclopramide—Asthenia—Vincristine—lymphatic system cancer	0.00251	0.00268	CcSEcCtD
Metoclopramide—Diarrhoea—Carmustine—lymphatic system cancer	0.00251	0.00268	CcSEcCtD
Metoclopramide—Nausea—Bleomycin—lymphatic system cancer	0.0025	0.00266	CcSEcCtD
Metoclopramide—Agranulocytosis—Methotrexate—lymphatic system cancer	0.00249	0.00265	CcSEcCtD
Metoclopramide—Asthenia—Mitoxantrone—lymphatic system cancer	0.00245	0.00261	CcSEcCtD
Metoclopramide—Dizziness—Carmustine—lymphatic system cancer	0.00243	0.00259	CcSEcCtD
Metoclopramide—Diarrhoea—Vincristine—lymphatic system cancer	0.0024	0.00256	CcSEcCtD
Metoclopramide—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00233	0.00249	CcSEcCtD
Metoclopramide—Dizziness—Vincristine—lymphatic system cancer	0.00232	0.00247	CcSEcCtD
Metoclopramide—Rash—Carmustine—lymphatic system cancer	0.00231	0.00247	CcSEcCtD
Metoclopramide—Dermatitis—Carmustine—lymphatic system cancer	0.00231	0.00246	CcSEcCtD
Metoclopramide—Visual impairment—Methotrexate—lymphatic system cancer	0.0023	0.00246	CcSEcCtD
Metoclopramide—Headache—Carmustine—lymphatic system cancer	0.0023	0.00245	CcSEcCtD
Metoclopramide—Rash—Vincristine—lymphatic system cancer	0.00221	0.00235	CcSEcCtD
Metoclopramide—Dermatitis—Vincristine—lymphatic system cancer	0.00221	0.00235	CcSEcCtD
Metoclopramide—Headache—Vincristine—lymphatic system cancer	0.00219	0.00234	CcSEcCtD
Metoclopramide—Nausea—Carmustine—lymphatic system cancer	0.00218	0.00232	CcSEcCtD
Metoclopramide—Rash—Mitoxantrone—lymphatic system cancer	0.00215	0.00229	CcSEcCtD
Metoclopramide—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00215	0.00229	CcSEcCtD
Metoclopramide—Headache—Mitoxantrone—lymphatic system cancer	0.00214	0.00228	CcSEcCtD
Metoclopramide—Nausea—Vincristine—lymphatic system cancer	0.00208	0.00222	CcSEcCtD
Metoclopramide—Nausea—Mitoxantrone—lymphatic system cancer	0.00203	0.00216	CcSEcCtD
Metoclopramide—Leukopenia—Methotrexate—lymphatic system cancer	0.00186	0.00199	CcSEcCtD
Metoclopramide—Convulsion—Methotrexate—lymphatic system cancer	0.0018	0.00192	CcSEcCtD
Metoclopramide—Confusional state—Methotrexate—lymphatic system cancer	0.00171	0.00183	CcSEcCtD
Metoclopramide—Hypotension—Methotrexate—lymphatic system cancer	0.00159	0.00169	CcSEcCtD
Metoclopramide—Insomnia—Methotrexate—lymphatic system cancer	0.00154	0.00164	CcSEcCtD
Metoclopramide—Dyspnoea—Methotrexate—lymphatic system cancer	0.00151	0.00162	CcSEcCtD
Metoclopramide—Somnolence—Methotrexate—lymphatic system cancer	0.00151	0.00161	CcSEcCtD
Metoclopramide—Fatigue—Methotrexate—lymphatic system cancer	0.00146	0.00156	CcSEcCtD
Metoclopramide—Feeling abnormal—Methotrexate—lymphatic system cancer	0.0014	0.00149	CcSEcCtD
Metoclopramide—Urticaria—Methotrexate—lymphatic system cancer	0.00135	0.00144	CcSEcCtD
Metoclopramide—Body temperature increased—Methotrexate—lymphatic system cancer	0.00134	0.00143	CcSEcCtD
Metoclopramide—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00125	0.00134	CcSEcCtD
Metoclopramide—Asthenia—Methotrexate—lymphatic system cancer	0.00122	0.0013	CcSEcCtD
Metoclopramide—Diarrhoea—Methotrexate—lymphatic system cancer	0.00116	0.00124	CcSEcCtD
Metoclopramide—Dizziness—Methotrexate—lymphatic system cancer	0.00112	0.0012	CcSEcCtD
Metoclopramide—Rash—Methotrexate—lymphatic system cancer	0.00107	0.00114	CcSEcCtD
Metoclopramide—Dermatitis—Methotrexate—lymphatic system cancer	0.00107	0.00114	CcSEcCtD
Metoclopramide—Headache—Methotrexate—lymphatic system cancer	0.00106	0.00114	CcSEcCtD
Metoclopramide—Nausea—Methotrexate—lymphatic system cancer	0.00101	0.00108	CcSEcCtD
